Study of Modifiable Risk Factors for Acute Lower Respiratory Tract Infection in Children Aged 2 Months to 5 Years
International Journal of Current Pharmaceutical Review and Research · 15.03.2026 · 18 (03)
DOI: 10.25258/ijcpr.18.3.102 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 15.03.2026. Verfasst von Poojitha S. und 2 weiteren Autor:innen.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Acute lower respiratory tract infections (ALRTI) remain a leading cause of under-five mortality globally, particularly in low- and middle-income countries where preventable socioeconomic and environmental risk factors persist.
Objective
To identify modifiable determinants associated with ALRTI severity among children aged 2 months to 5 years.
Methods
This hospital-based cross-sectional study included 100 children diagnosed with ALRTI over a one-year period. Sociodemographic variables, immunization status, breastfeeding practices, and environmental exposures were assessed using a structured proforma. Statistical analysis was performed and chi-square test; p
Zitieren
APA
S., P., K., S. B., & G., S. (2026). Study of Modifiable Risk Factors for Acute Lower Respiratory Tract Infection in Children Aged 2 Months to 5 Years. International Journal of Current Pharmaceutical Review and Research, 18(03). https://doi.org/10.25258/ijcpr.18.3.102
Vancouver
S. P, K. SB, G. S. Study of Modifiable Risk Factors for Acute Lower Respiratory Tract Infection in Children Aged 2 Months to 5 Years. International Journal of Current Pharmaceutical Review and Research. 2026;18(03). doi:10.25258/ijcpr.18.3.102
BibTeX
@article{S2026,
author = {S., Poojitha and K., Sahana B. and G., Sneha},
title = {Study of Modifiable Risk Factors for Acute Lower Respiratory Tract Infection in Children Aged 2 Months to 5 Years},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {03},
doi = {10.25258/ijcpr.18.3.102}
}
EUVIMED